The Vaccine Product, PTX-COVID19-B mRNA Humoral Vaccine, is intended for prevention of COVID-19 in a general population.

This Phase 1 study is designed to evaluate the safety, tolerability, and immunogenicity of PTX-COVID19-B vaccine in 60 healthy seronegative adults aged 18 to 64.